Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-326P (RNA, U6 small nuclear 326, pseudogene) is a processed pseudogene locus found in the human genome, deriving from a genomic duplication of the highly conserved U6 small nuclear RNA gene[2][3]. The functional U6 snRNA is an essential component of the spliceosome, responsible for intron removal from precursor mRNA during post-transcriptional modification in the nucleus[3]. Pseudogenes like RNU6-326P are typically non-coding and do not produce functional RNA or protein products. While some pseudogenes have been shown to participate in limited regulatory functions, such as competitive endogenous RNA mechanisms, there is no evidence for such activity from RNU6-326P specifically[4][6]. It is not considered a therapeutic target, does not interact with drugs, and is not used as a biomarker. Its presence in the genome reflects the evolutionary importance of U6 snRNA, but as a pseudogene, RNU6-326P is presumed biologically inert. If you require information about the *functional U6 snRNA* as a drug target, that would be a distinct entry, as the pseudogene itself does not have therapeutic relevance[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 326, pseudogene (RNU6-326P).